Torres Denice 4

What Happened Denice Torres, a director of Celldex Therapeutics, received a grant of 26,000 derivative securities (stock options) on June 25, 2026. The Form 4 reports the acquisition as 26,000 shares at $0.00 (derivative), with a footnote indicating the award was an option granted under the company's 2021 Omnibus Equity Incentive Plan. This was an award (compensation), not an open‑market purchase or sale, and no cash changed hands at grant.

Key Details

• Transaction date: 2026-06-25; Form 4 filed: 2026-06-29 (filed within the standard 2-business-day Form 4 window).
• Reported transaction: Grant/award (derivative) of 26,000 shares @ $0.00; total reported cash = $0.
• Footnote: Grant represents options issued under the 2021 Omnibus Equity Incentive Plan.
• Shares owned after transaction: not specified in the supplied filing details.
• Transaction type: A = Award/Grant (not a purchase/sale or gift).

Context This filing documents an options award, typically a component of director compensation. Such grants generally vest over time and do not represent an immediate market purchase or sale of stock; they do not necessarily signal a near‑term trading intent. For retail investors, awards are common and should be interpreted differently than open‑market purchases (which can be a stronger signal of an insider’s personal conviction).